コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ecifically inhibit the CRISPR-Cas9 system of Neisseria meningitidis.
2 s with N. lactamica prevents colonization by Neisseria meningitidis.
3 , influenza, Mycobacterium tuberculosis, and Neisseria meningitidis.
4 sing a dynamic transmission model of group A Neisseria meningitidis.
5 cillus anthracis, Neisseria gonorrhoeae, and Neisseria meningitidis.
6 l investigations frequently fail to identify Neisseria meningitidis.
7 ningococcal disease caused by infection with Neisseria meningitidis.
8 orms of ClpP from the Gram-negative pathogen Neisseria meningitidis.
9 an unexpectedly versatile Cas9 protein from Neisseria meningitidis.
10 nse of primary human meningothelial cells to Neisseria meningitidis.
11 key virulence factor and vaccine antigen of Neisseria meningitidis.
12 rm kinetic studies on PglL, the O-OTase from Neisseria meningitidis.
13 ream infection caused by the human pathogen, Neisseria meningitidis.
14 s catalysed by three DsbA oxidoreductases in Neisseria meningitidis.
15 ond most prevalent outer membrane protein in Neisseria meningitidis.
16 genetic island (GGI), as do a few strains of Neisseria meningitidis.
17 y to polymyxin B, as reported previously for Neisseria meningitidis.
18 nt mechanism of such phase variation (PV) in Neisseria meningitidis.
19 infection with the important human pathogen Neisseria meningitidis.
20 noclonal antibodies (MAbs) with encapsulated Neisseria meningitidis.
21 ival of infections with certain serotypes of Neisseria meningitidis.
22 ndonuclease paralogues in the human pathogen Neisseria meningitidis.
23 the porin PorB from the pathogenic bacterium Neisseria meningitidis.
24 rial pathogens including Vibrio cholerae and Neisseria meningitidis.
25 ation rates with Streptococcus pneumoniae or Neisseria meningitidis.
26 ; for Listeria monocytogenes, 0.12/0.12; for Neisseria meningitidis, 0.12/0.25; for Haemophilus spp.,
28 % (3790/6286) of bacterial meningitis cases: Neisseria meningitidis (1350 cases, 22%), Streptococcus
30 le dynamic regulation mechanism observed for Neisseria meningitidis 3-deoxy-d-arabino-heptulosonate 7
33 allelic profiles to characterize strains of Neisseria meningitidis, a major cause of bacterial menin
34 of human umbilical vein endothelial cells or Neisseria meningitidis after incubation with human serum
35 e Control and Prevention for the analysis of Neisseria meningitidis and Bordetella bronchiseptica gen
37 cillin-tazobactam, cefepime, and gentamicin, Neisseria meningitidis and ceftriaxone, and Haemophilus
39 ownregulates complement activation, binds to Neisseria meningitidis and increases resistance to serum
40 eficiency and compares it to studies done on Neisseria meningitidis and Moraxella catarrhalis; the tw
41 hown that the lipooligosaccharide (LOS) from Neisseria meningitidis and N. gonorrhoeae engages the TL
42 erdin in AP activation on diverse strains of Neisseria meningitidis and N. gonorrhoeae specifically u
43 These would include the beta-proteobacteria Neisseria meningitidis and Neisseria gonnorhoeae, in whi
44 t activity against the Gram-negative species Neisseria meningitidis and Neisseria gonorrheae and impr
47 pathology, while the two pathogenic species, Neisseria meningitidis and Neisseria gonorrhoeae, stradd
49 coccus pneumoniae compared with responses to Neisseria meningitidis and that in each case, the bacter
50 such as the nitric oxide reductase (NorB) of Neisseria meningitidis and the flavohemoglobins (Hmp) of
51 e use the method to analyze the porB gene of Neisseria meningitidis and verify the inferences using p
52 des two pathogens, Neisseria gonorrhoeae and Neisseria meningitidis, and at least 13 species of comme
55 ry-confirmed Streptococcus pneumoniae (Spn), Neisseria meningitidis, and Haemophilus influenzae menin
56 ry tract pathogens Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae, but
60 Vaccines against Streptococcus pneumoniae, Neisseria meningitidis, and Hemophilus influenzae type b
61 ophilus influenzae type b (Hib), serogroup C Neisseria meningitidis, and multiple capsular serotypes
62 ten human-restricted Neisseria species two, Neisseria meningitidis, and Neisseria gonorrhoeae, cause
64 -MS assay identified Pseudomonas aeruginosa, Neisseria meningitidis, and Staphylococcus aureus; these
65 eported to occur in Lactobacillus plantarum, Neisseria meningitidis, and Streptococcus agalactiae, an
74 previously identified lipooligosaccharide on Neisseria meningitidis as an acceptor for complement C4b
76 that initiate complement-mediated killing of Neisseria meningitidis as they enter the bloodstream fro
77 dentified as a ligand for these molecules on Neisseria meningitidis As with N. meningitidis NspA (Nm-
79 crystal structure of an ASBT homologue from Neisseria meningitidis (ASBT(NM)) in detergent was repor
80 es of the substrate-bound ClpXP complex from Neisseria meningitidis at 2.3 to 3.3 angstrom resolution
81 d O-antigen capsular polysaccharide (CPS) of Neisseria meningitidis B (NmB) have been investigated by
83 domonas aeruginosa, Acinetobacter baumannii, Neisseria meningitidis, Bacteroides fragilis, Bacillus a
87 diated engulfment of Neisseria gonorrheae or Neisseria meningitidis by human cells and can offer deep
90 h intact, heat-killed cells of Gram-negative Neisseria meningitidis, capsular serogroup C (MenC) or G
91 , and AcrIIC3 proteins were found to inhibit Neisseria meningitidis Cas9 (NmeCas9) activity in bacter
99 lP, an autotransporter of spherically shaped Neisseria meningitidis contains the molecular informatio
100 lipid A phosphoethanolamine transferase from Neisseria meningitidis, determined to 2.75-A resolution.
101 ainment strategies for outbreaks of invasive Neisseria meningitidis disease are informed by serogroup
102 e (SPR) based biosensor for the detection of Neisseria meningitidis DNA employing Kretschmann configu
104 ningococcal disease (IMD) due to serogroup Y Neisseria meningitidis emerged in Europe during the 2000
108 ts sporadic nature and the high diversity of Neisseria meningitidis, epidemiological surveillance inc
109 ding patients with Streptococcus pneumoniae, Neisseria meningitidis, Escherichia coli, and Pseudomona
110 m, and understanding the mechanisms by which Neisseria meningitidis evades host innate and acquired i
111 antibodies raised against sheaths presenting Neisseria meningitidis factor H binding protein (fHbp) a
112 s 3 main recombinant proteins, including the Neisseria meningitidis factor H binding protein (fHbp),
113 with a radiolabeled lipooligosaccharide from Neisseria meningitidis for binding to LBP or to the clos
116 ce diversity in the Campylobacter jejuni and Neisseria meningitidis genomes encoded hypothetical prot
117 ta that the class III Fic protein NmFic from Neisseria meningitidis gets autoadenylylated in cis, the
119 ampaign was launched using a newly developed Neisseria meningitidis group A (NmA) polysaccharide-teta
120 ine containing the N-propionyl derivative of Neisseria meningitidis group B (MenB) capsular polysacch
121 S) or with LPS as a noncovalent complex with Neisseria meningitidis group B outer membrane protein (L
122 l meningitis (Haemophilus influenzae type b, Neisseria meningitidis group C and seven serotypes of St
124 as oropharyngeal carriage of disease-causing Neisseria meningitidis (group A, B, C, W, X, or Y) in st
125 ncluding pathogens such as Escherichia coli, Neisseria meningitidis, Haemophilus influenzae, and Past
127 eillance targeted meningitis cases caused by Neisseria meningitidis, Haemophilus influenzae, and Stre
128 terial meningitis, which is caused mainly by Neisseria meningitidis, Haemophilus influenzae, and Stre
129 terial infections (Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae, S suis)
132 e substrate complexes of heme oxygenase from Neisseria meningitidis has been systematically perturbed
134 ative bacteria, including the human pathogen Neisseria meningitidis, have evolved means to preferenti
137 H binding protein (fHbp) is a lipoprotein of Neisseria meningitidis important for the survival of the
138 pneumoniae, GBS, Listeria monocytogenes, or Neisseria meningitidis in cerebrospinal fluid or other n
139 dent responses except that made with group C Neisseria meningitidis; in the latter case, only peptide
140 ge infectivity potentiator (rMIP) protein of Neisseria meningitidis induces significant serum bacteri
143 specific protection against capsular group B Neisseria meningitidis infections, but the full breadth
161 We show that the closely related bacterium Neisseria meningitidis is also polyploid, while the comm
168 nt inhibitor factor H (fH) to the surface of Neisseria meningitidis is critical for evasion of innate
173 ron-regulated FetA outer membrane protein of Neisseria meningitidis is one of various outer membrane
175 The LTTR, CrgA, from the human pathogen Neisseria meningitidis, is upregulated during bacterial-
179 a genomic DNA sequence of lpt3, derived from Neisseria meningitidis MC58, to search the genomic seque
180 nation with glyco-conjugate capsular group C Neisseria meningitidis (Men C) vaccines in infancy.
184 absence of an effective vaccine, serogroup B Neisseria meningitidis (MenB) remains a major cause of i
186 (pneumococcus), Haemophilus influenzae, and Neisseria meningitidis (meningococcus) was performed by
187 Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus
188 ing Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus
189 of Streptococcus pneumoniae (pneumococcus), Neisseria meningitidis (meningococcus), and Haemophilus
191 ce identity, PilE is structurally similar to Neisseria meningitidis minor pilins PilXNm and PilVNm, r
192 lation of lipopolysaccharide-null mutants in Neisseria meningitidis, Moraxella catarrhalis, and most
193 tococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, Mycoplasma pneumoniae, Mycobacte
196 s present within the obligate human pathogen Neisseria meningitidis, NApe and NExo, are important for
198 nships among three closely related bacteria, Neisseria meningitidis, Neisseria gonorrhoeae and Neisse
199 ajor human pathogens Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Helicobac
201 evasion is an important survival strategy of Neisseria meningitidis (Nm) during colonization and infe
210 ed cases of meningitis, 5590 were confirmed: Neisseria meningitidis ([Nm] 85%), Streptococcus pneumon
212 The conjugate vaccine against serogroup A Neisseria meningitidis (NmA), MenAfriVac, was first intr
213 ed Cas9s to identify a compact ortholog from Neisseria meningitidis-Nme2Cas9-that recognizes a simple
216 neither inactivated, unencapsulated, intact Neisseria meningitidis nor Streptococcus agalactiae inhi
218 lonization of the upper respiratory tract by Neisseria meningitidis occurs despite elicitation of ada
219 duals cocolonized by Neisseria lactamica and Neisseria meningitidis One HGT event resulted in the acq
220 al disease caused by ciprofloxacin-resistant Neisseria meningitidis, one in North Dakota and two in M
224 rs of bacterial pathogenic strains including Neisseria meningitidis, Pseudomonas aeruginosa and Esche
225 ion of a purified polysialyltransferase from Neisseria meningitidis (PST(Nm)) to the extracellular en
226 t infectious diseases over the past century, Neisseria meningitidis remains a major causative agent o
227 he availability of antibiotics and vaccines, Neisseria meningitidis remains a major cause of meningit
228 Inactivation of the misR/misS system in Neisseria meningitidis results in the loss of phosphoryl
229 uman pathogens, Streptococcus pneumoniae and Neisseria meningitidis, revealed both previously identif
232 ing in 2010, the burden of meningitis due to Neisseria meningitidis serogroup A (NmA) has substantial
233 serological correlates of protection against Neisseria meningitidis serogroup A (NmA) in Burkina Faso
235 ecially in the African meningitis belt where Neisseria meningitidis serogroup A historically caused l
236 the countries of the meningitis belt, where Neisseria meningitidis serogroup A historically caused l
239 rrelate of protection against infection with Neisseria meningitidis serogroup A, we use an assumed SB
243 Use of recently licensed vaccines against Neisseria meningitidis serogroup B (NmB) will depend par
244 The capsular polysaccharide of the pathogens Neisseria meningitidis serogroup B and of Escherichia co
246 abeled ([(14)C]-acetate) blebs purified from Neisseria meningitidis serogroup B with either human mon
247 tococcus pneumoniae, Listeria monocytogenes, Neisseria meningitidis serogroup B, Candida albicans, an
250 (at 2, 3, and 4 months or 2 and 4 months) or Neisseria meningitidis serogroup C monovalent meningococ
251 Acetylated sialic acid has been found in the Neisseria meningitidis serogroup W (NmW) capsular polysa
253 he United Kingdom due to a sublineage of the Neisseria meningitidis serogroup W ST-11 clonal complex
254 d States, South Africa, and Israel caused by Neisseria meningitidis serogroup Y (NmY) was greater tha
255 vasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup Y has increased in Euro
256 esponse to i.p.-injected intact, heat-killed Neisseria meningitidis, serogroup C (MenC), a gram-negat
257 des of recombinant capsular polymerases from Neisseria meningitidis serogroups A (CsaB) and X (CsxA)
259 ve meningococcal disease is mainly caused by Neisseria meningitidis serogroups A, B, C, X, W, and Y.
260 al virulence determinants of disease causing Neisseria meningitidis species are their extracellular p
261 o human pathogens, Neisseria gonorrhoeae and Neisseria meningitidis, stimulate PS/gammaS processing o
262 The native lipooligosaccharide (LOS) from Neisseria meningitidis strain 89I was analyzed by matrix
264 age prevention against antigenically diverse Neisseria meningitidis strains and to compare this prote
266 membrane vesicle (OMV) vaccines from mutant Neisseria meningitidis strains engineered to overexpress
269 mophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus pneumoniae, Strept
270 erized a TE6 thioesterase from the bacterium Neisseria meningitidis Structural analysis with X-ray cr
271 his reveals how the important human pathogen Neisseria meningitidis subverts immune responses by mimi
272 ned H influenzae type b and capsular group C Neisseria meningitidis tetanus toxoid conjugate vaccine
273 iochemical study of the AP endonuclease from Neisseria meningitidis that has allowed us to capture st
275 ccus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis, the 3 most common bacteria causi
277 sm of action has been studied extensively in Neisseria meningitidis, the specific subset of genes tha
278 o the closely related opportunistic pathogen Neisseria meningitidis, there is an absence of adaptive
279 d from the surface of the bacterial pathogen Neisseria meningitidis; they play a key role in adhesion
280 The ability of the human bacterial pathogen Neisseria meningitidis to cause invasive disease depends
284 method for the direct quantification of two Neisseria meningitidis vaccine antigens, in mono- and mu
285 Gram-negative bacterial pathogens including Neisseria meningitidis, Vibrio cholerae, and Salmonella
286 tor H binding protein (FHbp) is an important Neisseria meningitidis virulence factor that binds a neg
289 NmLgtB-B beta1-4 galactosyltransferase from Neisseria meningitidis we demonstrate fast and robust ac
290 egative pathogens Haemophilus influenzae and Neisseria meningitidis We hypothesized that activation o
291 ere, using a distinct CRISPR-Cas system from Neisseria meningitidis, we demonstrate efficient targeti
292 ausative agent of meningitis and septicemia, Neisseria meningitidis, we showed that the Pfs reaction
293 n antigenic variation (Av) of two strains of Neisseria meningitidis were determined using an unbiased
295 cord by a number of microorganisms including Neisseria meningitidis, which can lead to permanent neur
296 a family of outer membrane lipoproteins from Neisseria meningitidis, which elicits bactericidal antib
298 ere we expressed the gene encoding LpxA from Neisseria meningitidis, which specifically attaches 3OH-
299 abeling of hexaacylated endotoxin (LOS) from Neisseria meningitidis with [(13)C]acetate allowed the u